#HVO hVIVO PLC – Euronext cancellation August 5, 2024 – Posted in: hVIVO (HVO), Vela Technologies Plc (VELA) – Tags: contract, disease, euronext, infectious, organisation, research, respiratory, testing, trading

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its intention to cancel its admission (“the Cancellation”) to trading on Euronext Growth.

As hVIVO’s primary operations, along with the majority of its employees and investor base, are in the UK, the Board has decided to consolidate trading of the Company’s stock to its primary listing on the AIM Market of the London Stock Exchange. The Cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on hVIVO’s Ordinary Shares which will continue to trade on AIM under the ticker “HVO”.

In accordance with the Euronext Growth Rules, the Company has notified Euronext of the proposed Cancellation. Under the Euronext Growth Rules, the Cancellation can only take place after the expiry of a minimum period of twenty Business Days from the date on which notice of the Cancellation is given. Accordingly, it is intended that the Cancellation will become effective at 7.00 a.m. on 2 September 2024.

For further information please contact: